Wu, S., Ma, L., Wang, J., Wen, X., Zheng, M., Xu, B., Ma, H., Wang, Y., Su, L. (2025). Orelabrutinib plus rituximab-based chemoimmunotherapy regimens in relapsed or refractory marginal zone lymphoma: A multicentric phase II trial. Blood. https://doi.org/10.1182/blood-2025-7117